Results 71 to 80 of about 5,464,336 (251)

Public Health Surveillance for Adverse Events Following Covid-19 Vaccination in Africa: Rare Adverse Events and Fatal Cases Following COVID-19 Vaccination in Africa

, 2022
Background: The death toll and economic disaster caused by SARS-CoV-2/ COVID-19 is still on the rise globally and in Africa with a case fatality ratio (CFR), 2.58 from 220,958 deaths out of 8,556,890 cases recorded across the continent as of 14th ...
Elelu, Nusirat, Mosbah, Rasha, Fasina, Folorunsho, Razouqi, Youssef, Salako, Babatunde, Mhgoob, Zuhal, Ntirenganya, Lazare, Ajayi, Tunde, Elnadi, Hager, Odetokun, Ismail, Eyedo, Joseph, Awiagah, Kwame, Gachara, George, Nyandwi, Jean, Maisara, Aala, Abioye, Ajibola, Mohamed, Yusuf, Mohamud, Wright, Kikelomo, Saibu, Morounke, Anjorin, AbdulAzeez   +19 more
core   +1 more source

Bridging the gap: a genetically validated avian chorioallantoic membrane platform for investigation of spontaneous circulating tumor cells

Molecular Oncology, EarlyView.
We established the avian chorioallantoic membrane (CAM) assay as a scalable in vivo model for studying circulating tumor cells (CTCs). Human gastrointestinal tumors spontaneously released genetically validated CTCs that were detected across multiple platforms, demonstrating that the CAM model provides an accessible tool for investigating early cancer ...
Dennis Roth, Rui P. L. Neves, Julia Geheb, Christian Ballmeyer, Nathalie Gaßmann, Kiki C. Andree, Monica Sudarsanam, Christiane Driemel, Celine Örencik, Andrè Franken, Eslam Elmaghraby, Sven H. Loosen, Roderburg Christoph, Sebastian Schoelch, Hans Neubauer, Wolfram T. Knoefel, Nikolas H. Stoecklein, Georg Fluegen   +17 more
wiley   +1 more source

Managing the adverse events of intravesical bacillus Calmette-Guérin therapy [PDF]

, 2015
This paper provides recommendations on the management of complications arising from intravesical treatment with bacillus Calmette-Guérin (BCG) for nonmuscle-invasive bladder tumors.
Decaestecker K, Oosterlinck W, Oosterlinck, Willem, Decaestecker, Karel   +3 more
core   +1 more source

Treatment with KCL‐286, a first‐in‐class retinoic acid receptor‐β (RARβ) agonist, ameliorates neuronal DNA damage and inflammation in a mouse model of Alzheimer's disease

FEBS Open Bio, EarlyView.
Repair of neuronal DNA damage in Alzheimer's disease by KCL‐286. (A) Amyloid‐β oligomers and plaques impair neuronal DNA repair pathways, leading to DNA double‐strand breaks and glial activation. (B) KCL‐286 activates RARβ/RXR signalling via retinoic acid response elements (RAREs), associated with increased BRCA1 expression, enhanced DNA repair and ...
Natasha Hill, Hassan Yousef Othman AlMuallim, Elouisa Maddock, Carl Hobbs, Earl Clarke, Maria B. Goncalves, Jonathan P. T. Corcoran   +6 more
wiley   +1 more source

From patient advocacy to patient‐driven research: Building active partnerships beginning at the bench to reach the bedside

FEBS Open Bio, EarlyView.
Research is strongest when conducted alongside patients, not just about them. Patient research organizations help integrate patient perspectives into research priorities, study design, and scientific meetings, leading to meaningful patient outcomes and development of relevant therapies.
Jenica H. Kakadia, Rachel Heilmann, Maximiliano Barrientos, Laura MacNeill, Ingrid Vallee, Sarah K. Schultz, Patrick O'Donoghue, Angelica A. Moresco, Victoria M. Siu, Ilka U. Heinemann   +9 more
wiley   +1 more source

Rapid assessment of Loa loa prevalence and its implications on onchocerciasis and lymphatic filariasis elimination programmes in Osun state, Nigeria

Discover Public Health
Loiasis remains a significant public health concern, particularly in regions co-endemic for onchocerciasis and lymphatic filariasis, where high Loa loa microfilaraemia increases the risk of Severe Adverse Events (SAE) following mass drug administration ...
Q. O. Adeshina, A. M. Rufai, O. G. Dauda, L. O. Busari, D. I. Azeez, Z. O. Iwalewa, O. O. Abuh, G. B. Jokanola, A. A. Ayannibi, M. M. Abdulsalam, Y. O. Yusuff, G. O. Ige, L. O. Adegoke, O. A. Surakat, K. A. Fasasi, M. A. Adeleke   +15 more
doaj   +1 more source

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan, Lei Zhou, Jingzi ZhangBao, Hongmei Tan, Zhouzhou Wang, Chao Quan   +5 more
wiley   +1 more source

A structural equation model of adverse events and length of stay in hospitals [PDF]

Adverse events in hospitals cause significant morbidity and mortality, and considerable effort has been invested into analysing their incidence and preventability. An unresolved issue in models of medical adverse events is potential endogeneity of length
Katharina Hauck, Xueyan Zhao
core  

Influenza Vaccination Responses in Disabled Stroke Patients: A Single‐Center Prospective Observational Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study aimed to investigate the immunological response to influenza vaccination, the incidence and severity of influenza infection, and the side effects of the vaccination in patients with ischemic stroke. Methods This prospective observational study was conducted between 2023 and 2024 at Ramathibodi Hospital.
Achiraya Pakngao, Sureerat Suwatcharangoon, Pintip Ngamjanyapron, Kobporn Boonnak, Thanitta Suangtamai, Porpon Rotjanapan   +5 more
wiley   +1 more source

Safety and Tolerability of Givinostat: Evidence From Real‐World and Clinical Practice

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective The aim of our study was to establish the prevalence of adverse events in a real‐world setting in boys living with Duchenne muscular dystrophy (DMD) treated with givinostat as part of an Expanded Access Program (EAP) in Italy. Methods The cohort included 90 ambulant boys, with age when treatment started between 6 and 23 years (mean ...
Marika Pane, Anna Capasso, Chiara Arpaia, Adele D’Amico, Emilio Albamonte, Federica Trucco, Maria Sframeli, Riccardo Masson, Francesca Magri, Luca Bello, Romina Venditti, Claudia Dosi, Michela Catteruccia, Michele Tosi, Claudio Bruno, Sonia Messina, Giacomo Comi, Elena Pegoraro, Valeria A. Sansone, Eugenio Mercuri   +19 more
wiley   +1 more source